Agenus Inc. – NASDAQ:AGEN
Founder-led company
Agenus stock price today
$4.6
+1.84
+67.27%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
Agenus stock price monthly change
-82.37%
month
Agenus stock price quarterly change
-82.37%
quarter
Agenus stock price yearly change
+245.56%
year
Agenus key metrics
Market Cap | 64.04M |
Enterprise value | 283.22M |
P/E | -1.71 |
EV/Sales | 1.95 |
EV/EBITDA | -1.32 |
Price/Sales | 2.66 |
Price/Book | -6.29 |
PEG ratio | N/A |
EPS | -13.05 |
Revenue | 161.41M |
EBITDA | -122.51M |
Income | -243.80M |
Revenue Q/Q | 22.28% |
Revenue Y/Y | 69.93% |
Profit margin | -217.44% |
Oper. margin | -179.72% |
Gross margin | 30.61% |
EBIT margin | -179.72% |
EBITDA margin | -75.9% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAgenus stock price history
Agenus stock forecast
Agenus financial statements
Average Price Target
$7
Potential upside: 52.17%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 25.29M | -73.43M | -290.28% |
|---|---|---|---|
| Sep 2023 | 24.31M | -62.20M | -255.82% |
| Dec 2023 | 83.80M | -46.29M | -55.24% |
| Mar 2024 | 28.00M | -61.88M | -220.98% |
| Jun 2023 | 383593000 | 460.35M | 120.01% |
|---|---|---|---|
| Sep 2023 | 335472000 | 450.76M | 134.37% |
| Dec 2023 | 313913000 | 462.29M | 147.27% |
| Mar 2024 | 256559000 | 446.88M | 174.18% |
| Jun 2023 | -44.48M | 517K | 38.26M |
|---|---|---|---|
| Sep 2023 | -65.23M | 11.54M | 18.03M |
| Dec 2023 | -40.40M | 2.82M | 7.31M |
| Mar 2024 | -38.19M | 229K | 14.83M |
Agenus alternative data
| Aug 2023 | 533 |
|---|---|
| Sep 2023 | 533 |
| Oct 2023 | 533 |
| Nov 2023 | 533 |
| Dec 2023 | 533 |
| Jan 2024 | 533 |
| Feb 2024 | 533 |
| Mar 2024 | 389 |
| Apr 2024 | 389 |
| May 2024 | 389 |
| Jun 2024 | 389 |
| Jul 2024 | 389 |
Agenus other data
100.00%
0.00%
of AGEN is owned by hedge funds
98
-56
84.15M
-93.34M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 295788 | 0 |
| Aug 2023 | 212730 | 0 |
| Oct 2023 | 37976 | 0 |
| Nov 2023 | 25000 | 0 |
| Feb 2024 | 500000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ARMEN GARO H director, officer.. | Common Stock | 500,000 | $0.65 | $324,000 | ||
Purchase | WIINBERG ULF director | Common Stock | 25,000 | $0.76 | $19,000 | ||
Purchase | AGENUS INC 10 percent owner | Common Stock | 429 | $1.1 | $471 | ||
Purchase | AGENUS INC 10 percent owner | Common Stock | 19,373 | $1.1 | $21,310 | ||
Purchase | AGENUS INC 10 percent owner | Common Stock | 3,173 | $1.1 | $3,487 | ||
Purchase | AGENUS INC 10 percent owner | Common Stock | 15,001 | $1.09 | $16,381 | ||
Purchase | AGENUS INC 10 percent owner | Common Stock | 29,678 | $1.52 | $45,022 | ||
Purchase | AGENUS INC 10 percent owner | Common Stock | 12,808 | $1.45 | $18,572 | ||
Purchase | AGENUS INC 10 percent owner | Common Stock | 170,244 | $1.54 | $262,857 | ||
Purchase | AGENUS INC 10 percent owner | Common Stock | 23,361 | $1.43 | $33,360 |
| Patent |
|---|
Grant Filling date: 2 Dec 2016 Issue date: 20 Sep 2022 |
Application Filling date: 24 Jan 2022 Issue date: 1 Sep 2022 |
Application Filling date: 24 Jan 2022 Issue date: 25 Aug 2022 |
Application Filling date: 24 Jan 2022 Issue date: 18 Aug 2022 |
Grant Utility: Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies Filling date: 2 Mar 2020 Issue date: 16 Aug 2022 |
Grant Filling date: 15 Jan 2020 Issue date: 2 Aug 2022 |
Application Filling date: 30 Dec 2021 Issue date: 28 Jul 2022 |
Grant Filling date: 9 May 2019 Issue date: 14 Jun 2022 |
Grant Filling date: 24 Apr 2020 Issue date: 31 May 2022 |
Grant Filling date: 7 Feb 2020 Issue date: 17 May 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q1 2023 9 May 2023 | Q1 2023 Earnings Call Transcript |
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Agenus: Multiple Milestones In The Second Half Of 2024
Time Is Running Out For Agenus To Raise Cash
Agenus: Taking Advantage Of The Risk-Reward Opportunity
Agenus: 2024 May Finally Be The Year For A Major Turnaround
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Agenus: Getting The Tough Decisions Right With Catalysts Ahead
Agenus Readies Comeback With Impressive Botensilimab Data
Biopharma Exposure In SVB Financial Group And Investor Strategy
-
What's the price of Agenus stock today?
One share of Agenus stock can currently be purchased for approximately $4.6.
-
When is Agenus's next earnings date?
Unfortunately, Agenus's (AGEN) next earnings date is currently unknown.
-
Does Agenus pay dividends?
No, Agenus does not pay dividends.
-
How much money does Agenus make?
Agenus has a market capitalization of 64.04M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 59.47% to 156.31M US dollars.
-
What is Agenus's stock symbol?
Agenus Inc. is traded on the NASDAQ under the ticker symbol "AGEN".
-
What is Agenus's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Agenus?
Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Agenus's key executives?
Agenus's management team includes the following people:
- Dr. Garo H. Armen Ph.D. Founder, Executive Chairman & Chief Executive Officer(age: 72, pay: $1,070,000)
- Ms. Christine M. Klaskin Vice President of Fin., Principal Financial Officer & Principal Accounting Officer(age: 59, pay: $362,970)
-
Is Agenus founder-led company?
Yes, Agenus is a company led by its founder Dr. Garo H. Armen Ph.D..
-
How many employees does Agenus have?
As Jul 2024, Agenus employs 389 workers.
-
When Agenus went public?
Agenus Inc. is publicly traded company for more then 25 years since IPO on 8 Feb 2000.
-
What is Agenus's official website?
The official website for Agenus is agenusbio.com.
-
Where are Agenus's headquarters?
Agenus is headquartered at 3 Forbes Road, Lexington, MA.
-
How can i contact Agenus?
Agenus's mailing address is 3 Forbes Road, Lexington, MA and company can be reached via phone at +7 816744400.
-
What is Agenus stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Agenus in the last 12 months, the avarage price target is $7. The average price target represents a 52.17% change from the last price of $4.6.
Agenus company profile:
Agenus Inc.
agenusbio.comExchange:
NASDAQ
Full time employees:
389
Industry:
Biotechnology
Sector:
Healthcare
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
3 Forbes Road
Lexington, MA 02421-7305
Lexington, MA 02421-7305
CIK: 0001098972
ISIN: US00847G7051
CUSIP: 00847G705
